A personalized plan is essential for safety and results : Peptide therapy is not a one-size-fits-all treatment
If you are taking insulin and starting a GLP-1 receptor agonist, your insulin dose may need to be reduced gradually under medical supervision
According to FDA prescribing information, these include nausea (occurring in 1544% of patients depending on the agent and dose), vomiting, diarrhea, constipation, and abdominal pain
#teamcarbs Back in the day it would not be unusual for me to order a whole sandwich of some sort that definitely had bacon and/or avocado and a super rich soup with the baguette AND a chocolate chip cookie
[4] Clinical practice typically involves reviewing medication history, assessing liver function, performing a full blood count, and considering haematological or hepatological referral when levels are markedly elevated without clear cause
However, fewer side effects does not automatically mean equally effective results. Label-guided slow titration already exists to balance both